These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 12621790)
1. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. Borenstein J; Yu HT; Wade S; Chiou CF; Rapkin A J Reprod Med; 2003 Feb; 48(2):79-85. PubMed ID: 12621790 [TBL] [Abstract][Full Text] [Related]
2. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms. Brown C; Ling F; Wan J J Reprod Med; 2002 Jan; 47(1):14-22. PubMed ID: 11838304 [TBL] [Abstract][Full Text] [Related]
3. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives]. Cianci A; De Leo V Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832 [TBL] [Abstract][Full Text] [Related]
4. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Apter D; Borsos A; Baumgärtner W; Melis GB; Vexiau-Robert D; Colligs-Hakert A; Palmer M; Kelly S Eur J Contracept Reprod Health Care; 2003 Mar; 8(1):37-51. PubMed ID: 12725674 [TBL] [Abstract][Full Text] [Related]
5. Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone. Dickerson V J Reprod Med; 2002 Nov; 47(11 Suppl):985-93. PubMed ID: 12497673 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578 [TBL] [Abstract][Full Text] [Related]
7. Added benefits of drospirenone for compliance. Foidart JM Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653 [TBL] [Abstract][Full Text] [Related]
8. A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight. Endrikat J; Sandri M; Gerlinger C; Rübig A; Schmidt W; Fortier M Eur J Contracept Reprod Health Care; 2007 Sep; 12(3):220-8. PubMed ID: 17763260 [TBL] [Abstract][Full Text] [Related]
9. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Coffee AL; Kuehl TJ; Willis S; Sulak PJ Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986 [TBL] [Abstract][Full Text] [Related]
10. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception. Borges LE; Andrade RP; Aldrighi JM; Guazelli C; Yazlle ME; Isaia CF; Petracco A; Peixoto FC; Camargos AF Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100 [TBL] [Abstract][Full Text] [Related]
11. YAZ and the novel progestin drospirenone. Mishell DR J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of Yasmin in premenstrual symptoms. Taneepanichskul S; Jaisamrarn U; Phupong V Arch Gynecol Obstet; 2007 Jun; 275(6):433-8. PubMed ID: 17111156 [TBL] [Abstract][Full Text] [Related]
13. Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada. Endrikat JS; Milchev NP; Kapamadzija A; Georgievska J; Gerlinger C; Schmidt W; Feroze S Contraception; 2009 Jun; 79(6):428-32. PubMed ID: 19442777 [TBL] [Abstract][Full Text] [Related]
14. Use of an oral contraceptive containing drospirenone in an extended regimen. Sillem M; Schneidereit R; Heithecker R; Mueck AO Eur J Contracept Reprod Health Care; 2003 Sep; 8(3):162-9. PubMed ID: 14667328 [TBL] [Abstract][Full Text] [Related]
15. A prospective follow-up of two 21/7 cycles followed by two extended regimen 84/7 cycles with contraceptive pills containing ethinyl estradiol and drospirenone. Seidman DS; Yeshaya A; Ber A; Amodai I; Feinstein I; Finkel I; Gordon N; Porat N; Samuel D; Shiran-Makler E; Wolman I Isr Med Assoc J; 2010 Jul; 12(7):400-5. PubMed ID: 20862819 [TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of drospirenone-ethinylestradiol on contraception in healthy Chinese women: a multicenter randomized controlled trial]. Fan GS; Bian ML; Cheng LN; Cao XM; Huang ZR; Han ZY; Jing XP; Li J; Wu SY; Xiong CL; Xiong ZA; Yue TF Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):38-44. PubMed ID: 19563061 [TBL] [Abstract][Full Text] [Related]
17. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Pearlstein TB; Bachmann GA; Zacur HA; Yonkers KA Contraception; 2005 Dec; 72(6):414-21. PubMed ID: 16307962 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder. Freeman EW Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404 [TBL] [Abstract][Full Text] [Related]
19. Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives. Coffee AL; Kuehl TJ; Sulak PJ Pharmacotherapy; 2008 May; 28(5):576-83. PubMed ID: 18447656 [TBL] [Abstract][Full Text] [Related]
20. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. Boschitsch E; Skarabis H; Wuttke W; Heithecker R Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]